About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials in Nashville | 763 Studies

Clinical Trials Breast CancerNashville

Breast Cancer Clinical Trials in Nashville

Find 763 clinical trials for breast cancer near Nashville, Tennessee. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 301-320 of 763 trials

CompletedPrognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast CancerRATIONALE: Biopsy of sentinel lymph nodes and bone marrow may improve the ability to detect and determine the extent of cancer.NCT00003854·Birmingham, Alabama and 115 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingRobotic vs. Open NSM for Early Stage Breast CancerThis study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.NCT05720039·Irvine, California and 14 others

CompletedUtilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBCThis study evaluates the performance of a blood test for detecting biomarkers in metastatic breast cancer patients at one clinic against standard testing.NCT02436772·Nashville, Tennessee

Active not recruitingA Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.NCT04622319·Anaheim, California and 481 others

CompletedStudy of Continuous OSI-906 DosingMulticenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.NCT00514007·Nashville, Tennessee and 1 other

TerminatedA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerThis is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients…NCT06568692·Los Angeles, California and 11 others

Active not recruitingAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibThe purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an…NCT02955940·Santa Monica, California and 8 others

Active not recruitingFirst-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments.NCT03401385·Los Angeles, California and 17 others

Active not recruitingStudy of Oral MRT-2359 in Selected Cancer PatientsThis Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung…NCT05546268·Scottsdale, Arizona and 16 others

TerminatedA Safety Study of SGN-2FF for Patients With Advanced Solid TumorsThis study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.NCT02952989·Birmingham, Alabama and 10 others

CompletedAbraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast CancerBreast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women.NCT01307891·Birmingham, Alabama and 9 others

CompletedDeveloping Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast CancerRATIONALE: Changing the genes in laboratory mice to create a living model of human breast cancer may help doctors learn more about breast cancer.NCT00897468·Nashville, Tennessee

Active not recruitingEndocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerThe purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor…NCT03155997·Birmingham, Alabama and 618 others

TerminatedGDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast CancerThis phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.NCT01918306·Birmingham, Alabama and 15 others

CompletedA Retrospective Breast Reconstruction StudyTo collect data on patients who have previously undergone breast reconstruction utilizing SimpliDerm and other HADMs.NCT04060134·Montgomery, Alabama and 4 others

TerminatedA Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsThe purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in…NCT02834247·La Jolla, California and 21 others

CompletedStudy of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerThe primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive…NCT01958021·Chandler, Arizona and 220 others

Active not recruitingA Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerThis study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with…NCT03332797·Aurora, Colorado and 22 others

RecruitingFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsStudy STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478…NCT05768139·Los Angeles, California and 64 others

TerminatedLapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerThis phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer.NCT01281163·New Haven, Connecticut and 4 others

PreviousPage 16 of 39Next

Other Conditions in Nashville

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma